North Carolina Medicaid spending on GLP-1 drugs

How much did North Carolina Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $590.0 million for GLP-1 drugs paid through North Carolina Medicaid in 2025, across at least 484,712 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 94 rows of 338, so these figures are floors.

Pharmacies were reimbursed at least $145.7 million for GLP-1 drugs paid through North Carolina Medicaid in 2026 (quarter 1 only, as posted so far), across at least 119,143 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 30 rows of 99, so these figures are floors.

By year and ingredient

2020at least $5,405,652No data$15,059,970at least $4,907,766at least $9,598,075$216,713$325,761at least $35,513,935
2021at least $11,432,717No dataat least $20,820,241at least $15,243,888at least $7,206,766$257,674$236,002at least $55,197,288
2022at least $20,297,910at least $481,471at least $17,338,350at least $42,774,398at least $2,965,291$338,642at least $180,209at least $84,376,271
2023at least $65,909,404at least $8,860,168at least $11,330,474at least $47,685,601at least $1,472,229$343,699at least $111,972at least $135,713,548
2024at least $176,242,640at least $31,430,608at least $3,581,408at least $35,035,200at least $668,410at least $341,131at least $121,363at least $247,420,759
2025at least $454,762,587at least $96,366,609at least $1,252,237at least $37,162,983at least $141,150at least $215,536at least $95,552at least $589,996,654
2026 (Q1)at least $100,252,181at least $36,269,768at least $200,173at least $8,920,564Suppressedat least $43,825$27,137at least $145,713,648

By product, 2025

Ozempicat least $175,108,845at least 156,49410 of 36
Rybelsusat least $5,541,605at least 4,3097 of 24
Wegovy$274,112,137203,0870 of 40
Mounjaroat least $68,650,159at least 58,98011 of 59
Zepboundat least $27,716,450at least 25,11113 of 52
Liraglutide (generic name listing)at least $602,956at least 1,12121 of 40
Saxendaat least $148,960at least 1162 of 5
Victozaat least $500,321at least 6857 of 15
Trulicityat least $37,162,983at least 34,3497 of 39
Bydureonat least $121,344at least 1262 of 4
Byettaat least $19,806at least 234 of 6
Exenatide (generic name listing)SuppressedSuppressed5 of 5
Soliquaat least $215,536at least 2354 of 8
Xultophyat least $95,552at least 761 of 5

By quarter, 2025

Q1 2025at least $133,426,103at least 111,20124 of 86
Q2 2025at least $170,514,405at least 138,73626 of 88
Q3 2025at least $196,390,971at least 157,17721 of 83
Q4 2025at least $89,665,176at least 77,59823 of 81

By quarter, 2026 (posted so far)

Q1 2026at least $145,713,648at least 119,14330 of 99

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.